Allergan Sustainability Profile
Allergan, officially known as Allergan plc, is a prominent global pharmaceutical company headquartered in the United States. Founded in 1948, Allergan has established itself as a leader in the biopharmaceutical industry, focusing on areas such as medical aesthetics, eye care, and neuroscience. The company is renowned for its innovative products, including the widely recognised Botox, which has transformed both cosmetic and therapeutic treatments. With major operational regions spanning North America, Europe, and Asia, Allergan has achieved significant milestones, including its acquisition by AbbVie in 2020, further solidifying its market position. The company’s commitment to research and development has led to a diverse portfolio of unique offerings, making it a key player in enhancing patient outcomes and quality of life.
DitchCarbon Score
How does Allergan's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Allergan's score of 39 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Allergan's reported carbon emissions
In 2017, Allergan reported total greenhouse gas emissions of approximately 88,190,000 kg CO2e for Scope 1, 46,800,000 kg CO2e for Scope 2 (market-based), and 250,000,000 kg CO2e for Scope 3 emissions. This data is cascaded from its parent company, AbbVie Inc., reflecting Allergan's position as a current subsidiary. The emissions for previous years show a consistent pattern, with 2016 emissions at about 85,464,000 kg CO2e (Scope 1), 50,279,000 kg CO2e (Scope 2), and 250,000,000 kg CO2e (Scope 3), and 2015 emissions at approximately 85,405,000 kg CO2e (Scope 1), 62,403,000 kg CO2e (Scope 2), and 250,000,000 kg CO2e (Scope 3). Despite the significant emissions figures, Allergan has not publicly disclosed specific reduction targets or initiatives as part of its climate commitments. The absence of documented reduction targets suggests a need for further transparency in their climate strategy. Allergan's emissions data is sourced from Allergan plc, with the overarching climate initiatives and targets potentially influenced by its parent company, AbbVie Inc. This context highlights the importance of corporate family relationships in understanding Allergan's environmental impact and commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2005 | 2010 | 2011 | 2012 | 2015 | 2016 | 2017 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 28,218,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 59,189,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Allergan's Industry?
How Carbon Intensive is Allergan's Location?
Allergan's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Allergan has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
